PHENTOLAMINE MESYLATE

Post-LOE

phentolamine mesylate

Hikma

ANDAINJECTIONINJECTABLE

Approved

Mar 1998

Lifecycle

Post-LOE

Competitive Pressure

30/100

Clinical Trials

Data completeness

3/8 — Basic

Drug data last refreshed 3h ago

$0.0BPart D

Mechanism of Action

Mechanism of action data is being enriched from DailyMed and FDA sources. Check back soon for updated drug intelligence.

Indications

Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.

Clinical Trials (4)

NCT04024891Phase 2Completed

Safety and Efficacy of Ophthalmic Phentolamine Mesylate to Reverse Pharmacologically Induced Mydriasis

Started Aug 2019

32 enrolled

MydriasisDilation

NCT03960866Phase 2Completed

Safety and Efficacy of Ophthalmic Phentolamine Mesylate in Glaucoma

Started May 2019

39 enrolled

Open Angle GlaucomaOcular Hypertension

NCT01703559Phase 2Completed

The Safety and Efficacy of Phentolamine Mesylate Ophthalmic Solution in Subjects With Severe Night Vision Disturbances

Started Sep 2011

60 enrolled

Night Vision ComplaintsDecrease in Night VisionDisturbance; Vision, Loss

NCT04004507Phase 2Completed

Single Dose Study of Phentolamine Mesylate Eye Drops in Patients With Severe Night Vision Disturbances

Started Aug 2007

24 enrolled

Decrease in Night VisionDisturbance; Vision, Loss

Worked on PHENTOLAMINE MESYLATE at Hikma? Share your interview experience or compensation data (+7 days Pro)

Data Sources

Drug label: DailyMed / FDA
Clinical trials: ClinicalTrials.gov
Patent data: FDA Orange Book
Spending data: CMS Medicare

The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.